The aim of this study was to evaluate the effectiveness of sitagliptin, alone or in combination with metformin, in kidney transplant patients with newly diagnosed new-onset diabetes mellitus after transplant who had inadequate glycemic control, compared with a group of patients receiving insulin glargine with special emphasis on weight gain. Newly diagnosed renal transplant patients with new-onset diabetes mellitus after a transplant was defined by a blood glucose ≥ 11.1 mmol/L after an oral glucose tolerance test were examined. They were treated with standard immunosuppression composed of triple therapy with tacrolimus or cyclosporine, mycophenolate mofetil or azathioprine, and prednisone. They had stable graft function for more than 6 months after the transplant. Patients with new-onset diabetes mellitus after transplant (n=28) whose glycemia was not controlled adequately with oral hypoglycemic agents (either alone or in combination) received oral sitagliptin 100 mg once daily in addition to existing therapy for 12 weeks. Patients who received insulin glargine as add-on therapy (n=17) served as the control group. Data analyses included glycated hemoglobin, fasting plasma glucose, lipid profile, body weight, and the occurrence of hypoglycemia. We found significant reductions in glycated hemoglobin and fasting plasma glucose values after 12 weeks of additional sitagliptin therapy that were comparable to those with insulin glargine. While the addition of stagliptin resulted in a small weight loss (0.4 kg), the addition of insulin glargine resulted in a weight gain (0.8 kg). The overall incidence of adverse experiences was low and generally mild in both groups. In a group of renal transplant recipients with new-onset diabetes mellitus after a transplant in whom glycemia was not controlled adequately by oral hypoglycemic agents, the addition of sitagliptin helped to achieve glycemic control similar to insulin glargine but with a marginal weight advantage.
Background: End-stage renal disease (ESRD) has significantly increased in developing countries such as Egypt. Diabetes mellitus is still the leading cause of ESRD, while numbers of hypertensive patients among that population have significantly risen. Materials and Methods: The data presented in this article were obtained from various nephrology centers in response to the specific questionnaires distributed by the researchers. Results: Hemodialysis is available in most parts of the country. Continuous ambulatory peritoneal dialysis and renal transplantation programs have been performed in few nephrology centers. Costs for dialysis and renal transplantation are still unaffordable for most patients with ESRD. Since the cost burden has significantly increased, nephrology services should be changed from curative medicine to preventive medicine. Currently, the Egyptian Ministry of Health plans to have a detection and prevention program for chronic kidney disease. Conclusion: These data give the impression that both incidence and prevalence rates of ESRD in various areas of Egypt are increasing over time, although the rates presented here are far lower than expected.
The performance of abbreviated Modification of Diet in Renal Disease formula (aMDRD) and the Cockroft–Gault adjusted for body surface (aCG) equations as compared with measured 125I-iothalamate glomerular filtration rate was analyzed in patients with stable renal transplantation (RTx) and in potential living kidney donors (LKD). One hundred and thirty-one patients had RTx and 150 were LKD. The paired t-test showed that the estimated glomerular filtration rate (GFR) values through the aMDRD and the corrected CG equations were significantly different from each other (p < 0.01). There were significant differences between GFRs estimated using aCG and aMDRD equations (p < 0.001) in both groups (RTx and LKD) of different ages. The Pearson correlation coefficient between aCG and aMDRD equations was good (0.77, p < 0.01), but the kappa coefficient was 0.39, indicating a low agreement between the two formulae. In RTx patients with GFR <60 mL/min/1.73 m2, the aMDRD equation performed better than the aCG formula with respect to bias (–0.6 vs. 3.0 mL/min/1.73 m2, respectively) and accuracy within 30% (72% vs. 56%, respectively) and 50% (91% vs. 73%, respectively). Similar results are reported for 48 diabetic RTx patients. In the LKD, the aMDRD equation significantly underestimated the measured GFR when compared with the aCG formula, with a bias of –8.0 versus 2.2 mL/min/1.73 m2, respectively (p < 0.05). We can conclude that the Cockroft and MDRD equations cannot be used interchangeably in clinical transplantation practice and in order to adjust drug doses.